Study of microRNAs in a Decompensated Cirrhosis (EmiC)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Cirrhotic patients are at higher risk of sepsis due to impaired innate and adaptive immune responses. Septic complications represent a major issue in the management of cirrhotic patients, with a 1-month mortality rate of 23%, which increases to 80% at 3 months in case of associated organ failure.
Delay to treatment initiation during a septic episode may increase the risk of complications and mortality of cirrhotic patients. However, the inappropriate use of antibiotics exposes cirrhotic patients to the risk of more severe infections due to multi-resistant organisms or fungi.
The use of diagnostic markers for sepsis is limited in the context of cirrhosis because of the lack of hepatic synthesis of these markers on the one hand and non-specific inflammation related to cirrhosis on the other hand.
Therefore, it is necessary to develop new tools for the early diagnosis of sepsis and appropriate management of cirrhotic patients.
The interest of microRNAs (miRNAs) in the diagnosis and prognosis of septic shock has been reported in the general population. No studies have described circulating miRNAs or reported their interest in the diagnosis of sepsis in a population of cirrhotic patients with acute decompensation (AD).
This preliminary study of 800 circulating miRNAs will be performed in a cohort of patients with acute cirrhosis decompensation, for whom the incidence of sepsis is estimated at 40%. The aim to evaluate the interest and feasibility of a larger study on the interest of circulating miRNAs in the early diagnosis of sepsis in cirrhotic patients. The long-term objective of this study is the development of biomarkers for the early management of cirrhotic patients with sepsis and the rationalization of antibiotic use to improve their prognosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients with cirrhosis (determined either by histopathology or by association of clinical signs of portal hypertension and hepatocellular insufficiency and radiological signs (dysmorphic liver, evidences of portal hypertension (collateral circulation, ascites)).
AND
-
Not refusing his / her participation in the study after information (or non-opposition of the person of confidence if the patient has a disorder of consciousness or impaired judgment (hepatic encephalopathy) at the time of inclusion) AND
-
Admitted within 48 hours for an episode of acute decompensation (acute decompensation group = AD group), which is defined by the sudden occurrence of one or more of the following clinical or biological symptoms:
- Jaundice
- Hepatic encephalopathy
- oedemato-ascitic decompensation
- Gastro-intestinal bleeding
- Acute renal failure (according to AKIN criteria (22)) and / or hyponatremia
- Degradation of hepatocellular functions (decrease of prothrombin time and factor V measured in blood, increase of bilirubinemia) OR
-
Outpatient follow-up for stable cirrhosis, not admitted in the last 6 months for an episode of acute cirrhosis decompensation (pathological control group)
Exclusion criteria
- Minor or major patient under guardianship or curatorship
- Pregnant women
- Patient deprived of liberty
- History of extra-digestive cancer
- History of hepatocellular carcinoma or other hepatobiliary cancer
- Chronic infection with Hepatitis B virus (defined by the presence of Antibodies to hepatitis B core antigen (anti-HBc) and the absence of Hepatitis B surface antibodies (anti-HBs)) identified by a recent serology (less than 6 months)
- Chronic Hepatitis C Virus infection or cured for less than 6 months
- Infection with the Human Immunodeficiency Virus identified by a recent serology (less than 6 months)
Trial design
444 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Fanny Lebossé, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal